fda warning letters compounding semaglutide september 2025 Compounded " semaglutide" is not FDA-approved FDA issues 30 warning letters – Beyond the Headlines: FDA Warning

RF and EP contributed with clinical measurements

In addition, many of these patients will have additional risk factors for delayed gastric emptying (for example, diabetes or obesity) which must be taken into consideration

The withdrawal period after stopping semaglutide or tirzepatide often brings appetite rebound, and a GLP-1 support supplement may help smooth that transition

Friction from mask wearing can impact healing

Would definitely recommend

Always check the specific storage instructions for your prescribed formulation and contact your GP or pharmacist if you have concerns about whether your medication has been stored correctly